Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet

Effects of Darbepoetin Alfa Administered Every Two Weeks on Hemoglobin and Quality of Life of Patients Receiving Chemotherapy

Jody Folloder
ONF 2005, 32(1), 81-91 DOI: 10.1188/05.ONF.81-91

Purpose/Objectives: To review the effects on hemoglobin and quality of life of an every-two-week (Q2W) regimen of the erythropoietic agent darbepoetin alfa for treating patients with chemotherapy-induced anemia.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or